Patents by Inventor Akiharu Isowaki
Akiharu Isowaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210060320Abstract: A method for administering a drug to a diseased portion is achieved in a short time and predominantly improves the administration amount (transdermal permeation amount) of the drug in treatment of eyelid disease or palpebral conjunctiva disease. The method for administering a drug for treatment of eyelid disease or palpebral conjunctiva disease includes a step of microneedle perforation by using a microneedle device into a tissue of the eyelid including a meibomian gland of a patient suffering from or suspected of having the disease, in which drug-containing coating is applied to at least a part of a surface of the microneedle, and the drug is a water-soluble drug.Type: ApplicationFiled: December 27, 2018Publication date: March 4, 2021Inventors: Teppei OSAKO, Koji KAWAHARA, Takahiro OGAWA, Akiharu ISOWAKI,, Tetsuo KIDA
-
Publication number: 20200138732Abstract: An adhesive skin patch with a support liner comprises at least a strip drug product and a release liner longer than the drug product. The support liner includes a backing film and an adhesive layer; the drug product is quadrilateral with two long sides being straight in parallel and two short sides each elliptical arcs convex outward; a longest interval between the two short sides is 20.0 mm or more and 50.0 mm or less, and an interval between the two long sides is 5.0 mm or more and 37.5 mm or less; and the elliptical arc has: an ellipse major axis of 20.0 mm or more and 50.0 mm or less, an ellipse minor axis of 14.8 mm or more and less than 50.0 mm, and the minor axis of at least 2.0 mm wider than the interval of the two long sides.Type: ApplicationFiled: June 22, 2018Publication date: May 7, 2020Inventors: Takao HIRAOKA, Atsushi MURATA, Koji KAWAHARA, Takahiro OGAWA, Akiharu ISOWAKI
-
Publication number: 20190167568Abstract: [PROBLEMS TO BE SOLVED] To provide a method of advantageously improving a transdermal permeation amount of a steroid drug to diseased portions when treating ophthalmic diseases such as chalazion, blepharitis, allergic conjunctivitis, vernal keratoconjunctivitis, and meibomian gland dysfunction. [SOLUTION] To provide the transdermal drug delivery system for administering a drug via the eyelid skins that have been treated with a microneedle array, featured in that the drug is a water-soluble steroid, and the transdermal drug delivery system is a water-containing base adhesive skin patch.Type: ApplicationFiled: June 29, 2017Publication date: June 6, 2019Applicants: SENJU USA, INC., NICHIBAN CO., LTD.Inventors: Takahiro OGAWA, Akiharu ISOWAKI, Tetsuo KIDA, Koji KAWAHARA, Emiko TESHIMA, Teppei OSAKO
-
Publication number: 20190099300Abstract: To provide an adhesive skin patch being allowed that a carrier layer being in close contact with a backing film layer is easily released after applying to an application site, so as to improve a handleability of the adhesive skin patch.Type: ApplicationFiled: March 30, 2017Publication date: April 4, 2019Inventors: Takahiro OGAWA, Akiharu ISOWAKI, Mariko OHTSU, Takao HIRAOKA, Chihiro KENMOCHI, Atsushi MURATA, Koji KAWAHARA
-
Patent number: 9211397Abstract: A patch for treatment of eyelid diseases that is provided with a support, a pressure-sensitive adhesive layer, and a release layer in this order, wherein (a) the pressure-sensitive adhesive layer includes the following (a-1) to (a-4): (a-1) a styrene-isoprene-styrene block copolymer, a tackifier resin, and a softening agent are contained; (a-2) a ratio (mass ratio) of the styrene-isoprene-styrene block copolymer and the tackifier resin is 1:2 to 1:4; (a-3) a content of the softening agent is 40% to 60% by mass; and (a-4) further 0.005% to 5% by mass of clobetasol or acid ester thereof is contained; and (b) the support has elastic modulus with a Young's modulus of 0.01 to 0.5 GPa: and a method for producing the patch for treatment of eyelid diseases including: forming a pressure-sensitive adhesive layer on a upper surface of a release layer.Type: GrantFiled: December 19, 2012Date of Patent: December 15, 2015Assignee: SENJU USA, INC.Inventors: Takahiro Ogawa, Akiharu Isowaki, Koji Kawahara, Takao Hiraoka, Mariko Tanaka, Chihiro Kenmochi
-
Patent number: 8900626Abstract: A transdermal drug delivery system comprising a steroid as an active agent, wherein the steroid may be clobetasol propionate, betamethasone dipropionate, amcinonide, or loteprednol etabonate. The transdermal drug delivery system also comprises a pressure-sensitive adhesive layer and a support, wherein the steroid is present in the pressure-sensitive adhesive layer, and wherein the pressure-sensitive adhesive layer is provided on a support. The transdermal drug delivery system may be applied onto the eyelid of a patient in need thereof, in order to treat a disease of the eyelid, such as chalazion, blepharitis or meibomian gland dysfunction.Type: GrantFiled: June 20, 2011Date of Patent: December 2, 2014Assignee: Senju USA, Inc.Inventors: Takahiro Ogawa, Akiharu Isowaki
-
Publication number: 20140171886Abstract: A patch for treatment of eyelid diseases that is provided with a support, a pressure-sensitive adhesive layer, and a release layer in this order, wherein (a) the pressure-sensitive adhesive layer includes the following (a-1) to (a-4): (a-1) a styrene-isoprene-styrene block copolymer, a tackifier resin, and a softening agent are contained; (a-2) a ratio (mass ratio) of the styrene-isoprene-styrene block copolymer and the tackifier resin is 1:2 to 1:4; (a-3) a content of the softening agent is 40% to 60% by mass; and (a-4) further 0.005% to 5% by mass of clobetasol or acid ester thereof is contained; and (b) the support has elastic modulus with a Young's modulus of 0.01 to 0.5 GPa: and a method for producing the patch for treatment of eyelid diseases including: forming a pressure-sensitive adhesive layer on a upper surface of a release layer.Type: ApplicationFiled: December 19, 2012Publication date: June 19, 2014Applicant: SENJU USA, INC.Inventors: Takahiro Ogawa, Akiharu Isowaki, Koji Kawahara, Takao Hiraoka, Mariko Tanaka, Chihiro Kenmochi
-
Publication number: 20120321673Abstract: A transdermal drug delivery system comprising a steroid as an active agent, wherein the steroid may be clobetasol propionate, betamethasone dipropionate, amcinonide, or loteprednol etabonate. The transdermal drug delivery system also comprises a pressure-sensitive adhesive layer and a support, wherein the steroid is present in the pressure-sensitive adhesive layer, and wherein the pressure-sensitive adhesive layer is provided on a support. The transdermal drug delivery system may be applied onto the eyelid of a patient in need thereof, in order to treat a disease of the eyelid, such as chalazion, blepharitis or meibomian gland dysfunction.Type: ApplicationFiled: June 20, 2011Publication date: December 20, 2012Inventors: Takahiro OGAWA, Akiharu Isowaki
-
Patent number: 8101654Abstract: The present invention provides a percutaneously absorptive preparation for preventing or treating allergic eye disease, which comprises olopatadine or a salt thereof as an active ingredient. In addition, the present invention provides a method for preventing or treating allergic eye disease, which comprises applying a percutaneously absorptive preparation comprising olopatadine or a salt thereof to the skin surface including the skin surface of an eyelid, thereby casing transfer of a therapeutically effective amount of olopatadine or a salt thereof from the preparation to an anterior ocular segment through the skin of the eyelid rather than a systemic blood flow. The present preparation can exert a pharmacological effect over a prolonged period by a single application, as compared to conventional preparations such as eye drops.Type: GrantFiled: July 7, 2006Date of Patent: January 24, 2012Assignee: Senju Pharmaceutical Co., Ltd.Inventors: Akiharu Isowaki, Tomoko Nakajima, Akira Ohtori
-
Publication number: 20100150992Abstract: A transdermal drug delivery system for treatment of ophthalmic diseases comprising a structure that a plaster layer containing a remedy for ophthalmic diseases is provided on a support, wherein the system is applied to a skin surface including a front surface of an eyelid to administer the remedy for ophthalmic diseases in the plaster layer to an ophthalmic topical tissue by percutaneous permeation substantially without being administered through a systemic blood flow. Use of the transdermal drug delivery system for treatment of ophthalmic diseases, comprising applying the transdermal drug delivery system to a skin surface including a front surface of an eyelid to transfer the remedy for ophthalmic diseases in the plaster layer to an ophthalmic topical tissue by percutaneous permeation substantially without being administered through a systemic blood flow, and a method for transferring the remedy for ophthalmic diseases to the ophthalmic topical tissue.Type: ApplicationFiled: February 25, 2010Publication date: June 17, 2010Inventors: Kohji Kawahara, Yasuhiko Aramomi, Akira Ohtori, Akiharu Isowaki
-
Publication number: 20090318422Abstract: The present invention provides an ophthalmic percutaneous absorption type preparation containing an ophthalmic drug and a vasoconstrictor, which can increase the amount of the ophthalmic drug transferred through the eyelid to a topical area in the eye, particularly the anterior segment of the eye such as conjunctiva, lacrimal fluid, aqueous humor, cornea and the like by administration to the skin surface of an eyelid.Type: ApplicationFiled: August 28, 2007Publication date: December 24, 2009Inventors: Akiharu Isowaki, Tomoko Nakajima, Akira Ohtori
-
Publication number: 20090220580Abstract: The present invention provides a percutaneous absorption formulation including a patch having an adhesive layer disposed on a substrate and the adhesive layer contains ketotifen fumarate and tris(hydroxymethyl)aminomethane, and the patch is packaged in a hygroscopic packaging material. In the percutaneous absorption formulation, tris(hydroxymethyl)aminomethane particularly selected from various basic substances is incorporated, and by packaging the patch in a hygroscopic packaging material, the percutaneous absorptivity and content stability of a drug can be simultaneously improved and the yellowing of the drug can be suppressed. These effects can be further improved by the incorporation of propyl gallate, the use of an adhesive layer including an SIS-based adhesive base and a rosin ester-based adhesion imparting resin, and/or the removal of oxygen from the atmosphere in the inside of the packaging material.Type: ApplicationFiled: April 20, 2005Publication date: September 3, 2009Applicant: SENJU PHARMACEUTICAL CO., LTD.Inventors: Kouji Kawahara, Yasuhiko Aramomi, Noriko Shimada, Akira Ohtori, Akiharu Isowaki
-
Publication number: 20090209632Abstract: The present invention provides a percutaneously absorptive preparation for preventing or treating allergic eye disease, which comprises olopatadine or a salt thereof as an active ingredient. In addition, the present invention provides a method for preventing or treating allergic eye disease, which comprises applying a percutaneously absorptive preparation comprising olopatadine or a salt thereof to the skin surface including the skin surface of an eyelid, thereby casing transfer of a therapeutically effective amount of olopatadine or a salt thereof from the preparation to an anterior ocular segment through the skin of the eyelid rather than a systemic blood flow. The present preparation can exert a pharmacological effect over a prolonged period by a single application, as compared to conventional preparations such as eye drops.Type: ApplicationFiled: July 7, 2006Publication date: August 20, 2009Inventors: Akiharu Isowaki, Tomoko Nakajima, Akira Ohtori
-
Publication number: 20090143359Abstract: The present invention provides a percutaneously absorptive preparation for preventing or treating allergic eye disease, which comprises epinastine or a salt thereof as an active ingredient. In addition, the present invention provides a method for preventing or treating allergic eye disease, which comprises applying a percutaneously absorptive preparation comprising epinastine or a salt thereof to the skin surface including the skin surface of an eyelid, thereby causing transfer of a therapeutically effective amount of epinastine or a salt thereof from the preparation to an anterior ocular segment through the skin of the eyelid rather than a systemic blood flow. The present preparation can exert a pharmacological effect over a prolonged period by a single application, as compared to conventional preparations such as eye drops.Type: ApplicationFiled: July 7, 2006Publication date: June 4, 2009Inventors: Akiharu Isowaki, Tomoko Nakajima, Akira Ohtori
-
Publication number: 20090082381Abstract: The present invention provides a percutaneously absorbable ophthalmic preparation that permits the retention of a therapeutically effective concentration of a heterocyclic spiro compound and a salt thereof for promoting lacrimation, and that produces less adverse reactions such as miosis. Specifically, the present invention provides a percutaneously absorbable ophthalmic preparation comprising as an active ingredient a heterocyclic spiro compound represented by the general formula (I): [wherein the symbols have the same definitions as those given in the description] or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 26, 2006Publication date: March 26, 2009Inventors: Akiharu Isowaki, Akira Ohtori
-
Publication number: 20070053964Abstract: A percutaneous absorption type ophthalmic preparation comprising muscarinic receptor agonist is prepared, which can promote lacrimal fluid secretion by administration to the skin surface of the eyelid, and which causes fewer side effects such as miosis, thereby to provide a percutaneous absorption type ophthalmic preparation capable of maintaining a therapeutically effective concentration of a muscarinic receptor agonist for promoting lacrimal fluid secretion, which is associated with fewer side effects such as miosis, and a method of promoting lacrimal fluid secretion by administering a percutaneous absorption type ophthalmic preparation containing a muscarinic receptor agonist to the skin surface of the eyelid.Type: ApplicationFiled: May 20, 2005Publication date: March 8, 2007Inventors: Akiharu Isowaki, Akira Ohtori
-
Patent number: 7052714Abstract: Ophthalmic adhesive preparations for percutaneous absorption to be used in treating diseases in the posterior parts of eye characterized by having a drug-containing layer which contains a drug to be delivered to the posterior parts of eye including the crystalline lens, the vitreous body, the uvea and the retina, together with a percutaneous sorbefacient comprising polyoxyethylene oleyl ether and/or isopropyl myristate uniformly dispersed in a base matrix.Type: GrantFiled: September 29, 2000Date of Patent: May 30, 2006Assignees: Senju Pharmaceutical Co., LTD, Kakuji TojoInventors: Kakuji Tojo, Akiharu Isowaki
-
Publication number: 20060036220Abstract: A transdermal drug delivery system for treatment of ophthalmic diseases comprising a structure that a plaster layer containing a remedy for ophthalmic diseases is provided on a support, wherein the system is applied to a skin surface including a front surface of an eyelid to administer the remedy for ophthalmic diseases in the plaster layer to an ophthalmic topical tissue by percutaneous permeation substantially without being administered through a systemic blood flow. Use of the transdermal drug delivery system for treatment of ophthalmic diseases, comprising applying the transdermal drug delivery system to a skin surface including a front surface of an eyelid to transfer the remedy for ophthalmic diseases in the plaster layer to an ophthalmic topical tissue by percutaneous permeation substantially without being administered through a systemic blood flow, and a method for transferring the remedy for ophthalmic diseases to the ophthalmic topical tissue.Type: ApplicationFiled: January 22, 2004Publication date: February 16, 2006Inventors: Kohji Kawahara, Yasuhiko Aramomi, Akira Ohtori, Akiharu Isowaki